We are looking for healthy participants for a study based in Oxford. The aim of the study is to validate a method of measuring a drug called ribavirin in the blood. Ribavirin is normally used to treat hepatitis C and other diseases (such as Lassa fever – a viral infection occurring in West Africa). Ribavirin has a well-established safety profile. The study involves administering a single oral dose of ribavirin. The study also involves inserting a cannula (a small plastic tube inserted into a vein) and taking five blood samples via the cannula, as well as taking several finger prick blood tests. You will be compensated for your time for taking part in the study. You will be required to be available for 7 hours over the course of one day, because of the time intervals between the different blood draws.
In order to qualify for the study, you should be:
- Male between the ages of 18 and 65 AND willing to use barrier contraception for 7 days after taking the ribavirin
- Female between the ages of 50-65 AND able to confirm that you have reached menopause
- Not currently taking any prescription or over the counter medications or herbal remedies
- Not currently taking part in any other pharmacological studies
- Not suffering from any of the following conditions:
- Blood disorders (e.g. thalassemia major, sickle cell anaemia)
- Cardiovascular disease
- Autoimmune hepatitis
- Psychiatric disease
- Known allergy to ribavirin
If you are interested in finding out more information about the study please contact Annelies Gillesen or Dr. Alex Salam by email or phone, firstname.lastname@example.org, email@example.com, 01865 612959.
Ethics approval R60902/RE001